Glepaglutide

Glepaglutide API

Glepaglutide is a long-acting GLP-2 analog developed for the treatment of short bowel syndrome (SBS). It enhances intestinal absorption and growth, helping patients reduce dependence on parenteral nutrition.

Mechanism & Research:

Glepaglutide binds to the glucagon-like peptide-2 receptor (GLP-2R) in the gut, promoting:
Mucosal growth and regeneration
Improved nutrient and fluid absorption
Reduced intestinal inflammation

Clinical studies have shown that Glepaglutide can increase intestinal function and improve quality of life in SBS patients.

API Features (Gentolex Group):

Long-acting peptide analog
Produced via solid-phase peptide synthesis (SPPS)
High purity (≥99%), GMP-like quality

Glepaglutide API is a promising therapy for intestinal failure and gut rehabilitation.